Moxonidine Sandoz

Moxonidine, the active ingredient in Moxonidine Sandoz, is an imidazoline receptor agonist presented as an oral dosage form for oral use. It is used to lower elevated blood pressure in adults with hypertension.

GNH USA supplies Moxonidine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is an antihypertensive agent that acts on central imidazoline I1 receptors to reduce sympathetic tone.

Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension, helping achieve target blood pressure levels.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: generalized tiredness. - Headache: mild to moderate intensity. - Nausea: upset stomach, sometimes with mild vomiting. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Liver dysfunction: elevated liver enzymes or hepatitis. - Syncope: fainting episodes. - Electrolyte imbalance: abnormal potassium or sodium levels.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal impairment: dose may need adjustment in moderate to severe kidney disease. - Elderly patients: start at lower dose and titrate cautiously. - Hepatic dysfunction: avoid in severe liver disease. - Discontinuation: do not stop abruptly without medical guidance. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines that affect blood pressure or central nervous system activity.

Major Interactions (Avoid): - Other central antihypertensives (e.g., clonidine, guanfacine): risk of additive hypotension. - Potent CYP2D6 inhibitors: may increase plasma levels of moxonidine.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, monitor electrolytes. - NSAIDs: can blunt antihypertensive response. - Beta‑blockers: additive blood pressure lowering, watch for bradycardia. - Lithium: increased risk of lithium toxicity. - Alcohol: may potentiate dizziness and hypotension.